Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 918123, 8 pages
http://dx.doi.org/10.1155/2015/918123
Research Article

Resveratrol Prevents Cardiovascular Complications in the SHR/STZ Rat by Reductions in Oxidative Stress and Inflammation

School of Medical and Applied Sciences, Central Queensland University, Building 81, Bruce Highway, Rockhampton, QLD 4701, Australia

Received 29 August 2014; Accepted 10 October 2014

Academic Editor: Hyun-Ock Pae

Copyright © 2015 Rebecca K. Vella et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organisation, “Diabetes fact sheet,” 2013, http://www.who.int/mediacentre/factsheets/fs312/en/.
  2. M. Buluc and E. Demirel-Yilmaz, “Resveratrol decreases calcium sensitivity of vascular smooth muscle and enhances cytosolic calcium increase in endothelium,” Vascular Pharmacology, vol. 44, no. 4, pp. 231–237, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. C. A. Schmitt and V. M. Dirsch, “Modulation of endothelial nitric oxide by plant-derived products,” Nitric Oxide-Biology and Chemistry, vol. 21, no. 2, pp. 77–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Pullen, A. Fenning, and F. Coulson, “Effects of resveratrol and nebivolol on isolated vascular and cardiac tissues from young rats,” Advances in Pharmacological Science, vol. 2014, Article ID 720386, 8 pages, 2014. View at Publisher · View at Google Scholar
  5. V. Chan, A. Fenning, A. Iyer, A. Hoey, and L. Brown, “Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats,” Current Pharmaceutical Biotechnology, vol. 12, no. 3, pp. 429–436, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Thirunavukkarasu, S. V. Penumathsa, S. Koneru et al., “Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase,” Free Radical Biology & Medicine, vol. 43, no. 5, pp. 720–729, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Lassila, B. J. Davis, T. J. Allen, L. M. Burrell, M. E. Cooper, and Z. Cao, “Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system,” Clinical Science, vol. 104, no. 4, pp. 341–347, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Jian, E. Fok, M. C. Cam, N. Sambandam, J. Yao, and B. Rodrigues, “Susceptibility of spontaneously hypertensive rats to the diabetogenic effects of streptozotocin,” Canadian Journal of Physiology and Pharmacology, vol. 74, no. 11, pp. 1215–1221, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. M. E. Cooper, T. J. Allen, P. Macmillan, L. Bach, G. Jerums, and A. E. Doyle, “Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat,” The American Journal of Hypertension, vol. 1, no. 1, pp. 5–10, 1988. View at Google Scholar · View at Scopus
  10. L. E. Wold, D. P. Relling, P. B. Colligan et al., “Characterization of contractile function in diabetic hypertensive cardiomyopathy in adult rat ventricular myocytes,” Journal of Molecular and Cellular Cardiology, vol. 33, no. 9, pp. 1719–1726, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. M. E. Christe and R. L. Rodgers, “Cardiac glucose and fatty acid oxidation in the streptozotocin-induced diabetic spontaneously hypertensive rat,” Hypertension, vol. 25, no. 2, pp. 235–241, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Black, A. D'Amore, A. Auden et al., “Chronic type 1 diabetes in spontaneously hypertensive rats leads to exacerbated cardiac fibrosis,” Cardiovascular Pathology, vol. 19, no. 6, pp. 361–370, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. A. Van Zwieten, K. L. Kam, A. J. Pijl, M. G. C. Hendriks, O. H. M. Beenen, and M. Pfaffendorf, “Hypertensive diabetic rats in pharmacological studies,” Pharmacological Research, vol. 33, no. 2, pp. 95–105, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. N. K. Cortas and N. W. Wakid, “Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method,” Clinical Chemistry, vol. 36, no. 8, pp. 1440–1443, 1990. View at Google Scholar · View at Scopus
  15. K. Claeson, G. Thorsén, and B. Karlberg, “Methyl malondialdehyde as an internal standard for the determination of malondialdehyde,” Journal of Chromatography B: Biomedical Sciences and Applications, vol. 751, no. 2, pp. 315–323, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. A. S. Sim, C. Salonikas, D. Naidoo, and D. E. L. Wilcken, “Improved method for plasma malondialdehyde measurement by high-performance liquid chromatography using methyl malondialdehyde as an internal standard,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 785, no. 2, pp. 337–344, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Fenning, G. Harrison, R. Rose'meyer, A. Hoey, and L. Brown, “L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 289, no. 4, pp. H1408–H1416, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Jadhav, W. Liang, J. Balsevich et al., “L-Tryptophan ethyl ester dilates small mesenteric arteries by inhibition of voltage-operated calcium channels in smooth muscle,” British Journal of Pharmacology, vol. 166, no. 1, pp. 232–242, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Sandhu, S. Ansar, and L. Edvinsson, “Comparison of MEK/ERK pathway inhibitors on the upregulation of vascular G-protein coupled receptors in rat cerebral arteries,” European Journal of Pharmacology, vol. 644, no. 1–3, pp. 128–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Huynh, H. Kiriazis, X.-J. Du et al., “Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice,” Free Radical Biology and Medicine, vol. 60, pp. 307–317, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. D. S. H. Bell, “Hypertension, diabetes, insulin resistance, and postprandial hyperglycemia,” Drug Development Research, vol. 67, no. 7, pp. 595–596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. M. R. Hayden and J. R. Sowers, “Hypertension in type 2 diabetes mellitus,” Insulin, vol. 1, no. 1, pp. 22–37, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. J. A. Baur and D. A. Sinclair, “Therapeutic potential of resveratrol: the in vivo evidence,” Nature Reviews Drug Discovery, vol. 5, no. 6, pp. 493–506, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Cao and Y. Li, “Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury,” European Journal of Pharmacology, vol. 489, no. 1-2, pp. 39–48, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Inglés, J. Gambini, M. G. Miguel et al., “PTEN mediates the antioxidant effect of resveratrol at nutritionally relevant concentrations,” BioMed Research International, vol. 2014, Article ID 580852, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Wallerath, G. Deckert, T. Ternes et al., “Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase,” Circulation, vol. 106, no. 13, pp. 1652–1658, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. S. R. Bhatt, M. F. Lokhandwala, and A. A. Banday, “Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats,” European Journal of Pharmacology, vol. 667, no. 1–3, pp. 258–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. S. C. Goh, O. L. Woodman, S. Pepe, A. H. Cao, C. Qin, and R. H. Ritchie, “The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms,” Antioxidants and Redox Signaling, vol. 9, no. 1, pp. 101–113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Palsamy and S. Subramanian, “Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic β-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats,” Journal of Cellular Physiology, vol. 224, no. 2, pp. 423–432, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Lu, L. Ma, L. Ruan et al., “Resveratrol differentially modulates inflammatory responses of microglia and astrocytes,” Journal of Neuroinflammation, vol. 7, article 46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Xu, Y. Wang, W. Cui et al., “Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-κB pathway,” International Journal of Endocrinology, vol. 2014, Article ID 289327, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Buttari, E. Profumo, L. Segoni et al., “Resveratrol counteracts inflammation in human M1 and M2 macrophages upon challenge with 7-oxo-cholesterol: potential therapeutic implications in atherosclerosis,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 257543, 12 pages, 2014. View at Publisher · View at Google Scholar
  34. M. Ajay and M. R. Mustafa, “Effects of ascorbic acid on impaired vascular reactivity in aortas isolated from age-matched hypertensive and diabetic rats,” Vascular Pharmacology, vol. 45, no. 2, pp. 127–133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Chamiot-Clerc, J. F. Renaud, and M. E. Safar, “Pulse pressure, aortic reactivity, and endothelium dysfunction in old hypertensive rats,” Hypertension, vol. 37, no. 2, pp. 313–321, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Le Brocq, S. J. Leslie, P. Milliken, and I. L. Megson, “Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities,” Antioxidants & Redox Signaling, vol. 10, no. 9, pp. 1631–1673, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Wu, S. Xia, B. Kalionis, W. Wan, and T. Sun, “The role of oxidative stress and inflammation in cardiovascular aging,” BioMed Research International, vol. 2014, Article ID 615312, 13 pages, 2014. View at Publisher · View at Google Scholar
  38. T. Baluchnejadmojarad and M. Roghani, “Chronic administration of genistein improves aortic reactivity of streptozotocin-diabetic rats: mode of action,” Vascular Pharmacology, vol. 49, no. 1, pp. 1–5, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Zhang, J. Zhang, Z. Ungvari, and C. Zhang, “Resveratrol improves endothelial function: role of TNFα and vascular oxidative stress,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 8, pp. 1164–1171, 2009. View at Publisher · View at Google Scholar · View at Scopus